Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

SARS-CoV-2 RNA and antibody detection in infected mothers’ breast milk

In a recent study published in the Journal of Medical Virology, Italian researchers investigated the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid (RNA) and antibodies (Abs) in the milk of breastfeeding mothers with SARS-CoV-2 infections.

14 Sep 2022

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

In a recent study posted to the bioRxiv* pre-print server, researchers from Washington University School of Medicine, Moderna, Inc, and the U.S. National Institutes of Health tested two bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on the messenger ribonucleic acid (mRNA) platform.

14 Sep 2022

Interactions between SIRT5 and SARS-CoV-2 Nsp14 protein

In a new study, researchers investigated the interactions between sirtuin 5 (SIRT5) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein (Nsp14) protein.

14 Sep 2022

What is the impact of COVID-19 treatments targeting intracellular Neu1?

In a new study, researchers assessed the impact of targeting intracellular Neu1 on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

COVID-19 risk substantially reduced in seniors who receive 4th mRNA booster

In a recent study published in the Annals of Internal Medicine, researchers in Singapore estimated the effectiveness of the second booster (fourth dose) vaccination with messenger ribonucleic acid (mRNA) vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections with the SARS-CoV-2 Omicron variant and associated hospitalizations with among individuals aged ≥80 years.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

Altered T-cell response in hemodialysis patients following third COVID-19 vaccine dose

Scientists define the immune responses against COVID-19 in HD patients who received three mRNA COVID-19 vaccine doses.

13 Sep 2022

How effective is vitamin D supplementation in COVID-19?

The current paper addresses the considerable evidence now supporting the efficacy of vitamin D in COVID-19, as well as its safety.

13 Sep 2022

Forecasting COVID-19 surges based on SARS-CoV-2 mutation surveillance

Researchers predicted surges in SARS-CoV-2 infections based on alterations in SARS-CoV-2 mutations.

13 Sep 2022

Transplacental passage of specific IgG in maternal SARS-CoV-2 infection

Researchers analyzed antibody profiles of mothers infected with SARS-CoV-2 and their offspring.

13 Sep 2022

First report of a SARS-CoV-2 variant with an ORF7a deletion that dominated an outbreak

In a recent study posted to the medRxiv* preprint server, researchers in Australia determined whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta-ORF7aΔ17del [open reading frame 7a protein with 17-nucleotide (nt) frameshift-inducing deletion] variant has a fitness advantage over the Delta variant lacking the ORF7aΔ17del deletion (Delta-ORF7aintact) and/or the SARS-CoV-2 lineage (A.2.2).

12 Sep 2022

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* server, researchers in Singapore and the United States demonstrated that intranasal (I.N.) delivery of a mucosal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination triggered a superior T cell response compared to an equivalent dose of antigen delivered by the subcutaneous (S.C.) route.

12 Sep 2022

Research supports use of FFP2/3 masks for HCWs caring for COVID-19 patients

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom assessed the aerobiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in United Kingdom (UK) hospitals and the impact of aerosol-generating procedures (AGP).

12 Sep 2022

Vaccines that induce mucosal immunity against SARS-CoV-2 are needed

In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom studied assessed plasma and nasal antibody (Ab) responses induced after a year of coronavirus disease 2019 (COVID-19)-associated hospitalization and the potential boost by subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in the United Kingdom (UK).

12 Sep 2022